A-192411

structure in first source

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Bennani, Youssef L: 1 article (02/2003)
2.	Dickman, Daniel A: 1 article (02/2003)
3.	Ding, Hong: 1 article (02/2003)
4.	Frost, David: 1 article (02/2003)
5.	Goldman, Robert C: 1 article (02/2003)
6.	Hasvold, Lisa: 1 article (02/2003)
7.	Lartey, Paul: 1 article (02/2003)
8.	Li, Qun: 1 article (02/2003)
9.	Meulbroek, Jonathan A: 1 article (02/2003)
10.	Nilius, Angela M: 1 article (02/2003)

1.	Pyelonephritis 02/10/2003 - "The efficacy of A-192411, administered intraperitoneally, was equivalent to amphotercin B at a 4-fold lower dose by weight in the systemic candidiasis models in mice, while the efficacy of A-192441 administered intravenously was equivalent to amphotercin B by weight in the Candida pyelonephritis model in rats. "
2.	Systemic candidiasis 02/10/2003 - "The efficacy of A-192411, administered intraperitoneally, was equivalent to amphotercin B at a 4-fold lower dose by weight in the systemic candidiasis models in mice, while the efficacy of A-192441 administered intravenously was equivalent to amphotercin B by weight in the Candida pyelonephritis model in rats. "
3.	Mycoses (Diseases, Fungus) 02/10/2003 - "The ability of the novel antifungal cyclic hexalipopetide A-192411 to treat fungal infections in rodents is presented. "